Table 2 Baseline Characteristics of Enrolled Participants (N = 25)
Participant Characteristic | n | Mean | % |
|---|---|---|---|
Years of age | Â | 46.4 | Â |
Male gender | 24 | Â | 96 |
Race/ethnicity | Â | Â | Â |
   Caucasian | 17 |  | 68 |
   African American | 4 |  | 16 |
   Latino | 4 |  | 16 |
Years HIV-infected | Â | 13.7 | Â |
CD4 cell count | Â | 494/mm3 | Â |
HIV RNA < 75 copies/mL | 19 | Â | 76 |
Months on HAART | Â | 82.3 | Â |
Target dyslipidemia-inducing agents | Â | Â | Â |
   lopinavir/ritonavir | 15 |  | 60 |
   atazanavir/ritonavir | 3 |  | 12 |
   tipranavir/ritonavir | 1 |  | 4 |
   fosamprenavir/ritonavir | 1 |  | 4 |
   efavirenz | 5 |  | 20 |
Months on target agent | Â | 19.0 | Â |
History of opportunistic infection | 13 | Â | 52 |
Cardiac risk factors | Â | Â | Â |
   Lipodystrophy | 13 |  | 52 |
   hypertension | 7 |  | 28 |
   family history of hypertension | 9 |  | 36 |
   family history of hyperlipidemia | 11 |  | 44 |
   tobacco smokers | 8 |  | 32 |
   former smokers | 7 |  | 28 |
   alcohol users | 15 |  | 60 |
   former alcohol users | 5 |  | 20 |
   illicit substance users | 14 |  | 56 |
   former illicit substance users | 7 |  | 28 |
Prior antihyperlipidemic use: | 9 | Â | 36 |